Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients

Annals of Hepatology

Volumn 7, Issue 2, 2008, Pages 152-156

  Otegbayo, Jesse A ^a,b   Taiwo, Babafemi O ^b,c   Akingbola, Titilola S ^d   Odaibo, Georgina N ^d   Adedapo, Kayode S ^e   Penugonda, Sudhir ^b,c   Adewole, Isaac F ^d   Olaleye, David O ^d   Murphy, Rob ^b,c   Kanki, Phyllis ^f  

^a Departments of Medicine

^b UNIVERSITY OF IBADAN   (Nigeria)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Haematology ^*

^e Chemical Pathology

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CD4; Hepatitis B; Hepatitis C; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; VIRUS RNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NIGERIA; RETROSPECTIVE STUDY; SEROPREVALENCE; SEX RATIO; VIRUS LOAD;

EID: 45349104044     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31872-1     Document Type: Article

References (27)

1. WHO (2003). World health report: 2003: shaping the future. Geneva. ISBN 92 4 156243 9.
2. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev 2007; 9(1): 25-39.
3. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.
4. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL. Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921-1926.
5. García-Samaniegorez Rodríguez M, Berenguer J, Rodríguez-Rosado R, Carbó J, Asensi V, Soriano V. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001 ; 96: 179-183.
6. Mariné-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004; 18(16): 2163-70.
7. Aceti A, Pasquazzi C, Zechini B, et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29(1): 41-8.
8. Thomas DL. Growing importance of liver disease in HIV-infected persons. Hepatology 2006; 43: S221-S229.
9. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007; 356: 1445-1454.
10. Braga P, Cardoso MR, Segurado AC. Gender differences in survival in an HIV/AIDS cohort from Sao Paulo, Brazil. AIDS Patient Care STDS 2007; 21: 321-328.
11. Hosegood V, Jaffar S, Bätzing-Feigenbaum J, Herbst K, Newell ML. Continued very high prevalence of HIV infection in rural KwaZulu-Natal, South Africa: a population-based longitudinal study. AIDS 2007; 2111: 1467-1472.
12. Seeley J, Grellier R, Barnett T. Gender and HIV/AIDS impact mitigation in sub-Saharan Africa-recognizing the constraints. SAHARA J 2004; 1: 87-98.
13. Ola SO, Ladipo MM, Otegbayo JA, Odaibo GN, Bamgboye EA, Nwaorgu OG, Shokunbi SW, Olaleye OD. Demographic factors in HIV infected patients seen at UCH, Ibadan, Nigeria. Afr J Med Med Sci 2005; 34: 297-301.
14. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166(15): 1632-41.
15. Sirisena ND, Njoku MO, Idoko JA, et al. Carriage rate of hepatitis-B surface antigen (HBsAg) in an urban community in Jos Plateau State, Nigeria. Niger Postgrad Med J 2002; 9: 7-10.
16. Uneke CJ, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH. Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz 2005; 100: 13-16.
17. Davis L, Weber D, Lemon S. Horizontal transmission of HBV. Lancet 1989: 889-93.
18. Drew JS, London WT, Lustbader ED, et al. Cross-reactivity between HBsAg and a male-associated antigen. Birth Defects 1978; 15: 91.
19. Zhou J, Dore GJ, Zhang F, et al. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007; 22(9): 1510-8.
20. Agwale SM, Tanimoto L, Womack C, et al. Prevalence of HCV coinfection in HIV-infected individuals in Nigeria and characterization of HCV genotypes. J Clin Virol 2004; 31Suppl 1: S3-6.
21. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35: 14-20.
22. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001; 26: 340-344.
23. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-5.
24. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 2004; 39: 1507-13.
25. Hershow RC, O'Driscoll PT, Handelsman E, et al. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis 2005; 40: 859-6.
26. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192(6): 992-1002.
27. Stebbing J, Waters L, Mandalia S, et al. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis 2005; 41(6): 906-1.